Literature DB >> 22933125

Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature.

Yasser Emad1, Yasser Ragab, Nashwa El-Shaarawy, Johannes J Rasker.   

Abstract

Transient osteoporosis of the hip (TOH), also referred to as transient bone marrow edema syndrome, is most common in middle-aged men and often after trivial trauma or sport-related injuries. Diagnosis is usually made by eliminating other possible causes of hip pain. Magnetic resonance imaging (MRI) plays an important role in diagnosis and demonstrates a typical pattern of bone marrow edema (BME) in the form of diffuse low signal on T1-weighted images and high signal on T2 fat-suppressed or short T1 inversion recovery images. No consensus exists about the management of TOH, as it may progress to avascular necrosis. We describe eight cases of TOH treated with alendronate resulting in improvement of pain and function and complete resolution of BME on MRI. The literature is reviewed regarding TOH and the relationship with bone marrow edema syndrome, avascular necrosis of the hip, and regional migratory osteoporosis. To our knowledge, this is the first report describing the improvement of this condition after of alendronate with documented radiological improvement on follow-up MRI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933125     DOI: 10.1007/s10067-012-2060-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  A clinicopathologic study of transient osteoporosis of the hip.

Authors:  T Yamamoto; T Kubo; Y Hirasawa; Y Noguchi; Y Iwamoto; K Sueishi
Journal:  Skeletal Radiol       Date:  1999-11       Impact factor: 2.199

2.  The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

Authors:  Kuo-An Lai; Wun-Jer Shen; Chyun-Yu Yang; Chung-Jung Shao; Jui-Ting Hsu; Ruey-Mo Lin
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

3.  Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.

Authors:  ThiThuyAn Nguyen; Margaret R Zacharin
Journal:  J Pediatr Endocrinol Metab       Date:  2006-02       Impact factor: 1.634

4.  Can MR imaging distinguish between transient osteoporosis of the femoral head and osteonecrosis?

Authors:  M L Richardson
Journal:  AJR Am J Roentgenol       Date:  1994-05       Impact factor: 3.959

5.  Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.

Authors:  S Agarwala; D Jain; V R Joshi; A Sule
Journal:  Rheumatology (Oxford)       Date:  2004-11-30       Impact factor: 7.580

Review 6.  MR imaging of bone marrow edema pattern: transient osteoporosis, transient bone marrow edema syndrome, or osteonecrosis.

Authors:  C W Hayes; W F Conway; W W Daniel
Journal:  Radiographics       Date:  1993-09       Impact factor: 5.333

7.  MR imaging of avascular necrosis and transient marrow edema of the femoral head.

Authors:  B E Vande Berg; J J Malghem; M A Labaisse; H M Noel; B E Maldague
Journal:  Radiographics       Date:  1993-05       Impact factor: 5.333

8.  Femoral capital osteonecrosis: MR finding of diffuse marrow abnormalities without focal lesions.

Authors:  D A Turner; A C Templeton; P M Selzer; A G Rosenberg; J P Petasnick
Journal:  Radiology       Date:  1989-04       Impact factor: 11.105

9.  Bone-marrow oedema syndrome and transient osteoporosis of the hip. An MRI-controlled study of treatment by core decompression.

Authors:  S Hofmann; A Engel; A Neuhold; K Leder; J Kramer; H Plenk
Journal:  J Bone Joint Surg Br       Date:  1993-03

10.  Distinguishing transient osteoporosis of the hip from avascular necrosis.

Authors:  Anita Balakrishnan; Emil H Schemitsch; Dawn Pearce; Michael D McKee
Journal:  Can J Surg       Date:  2003-06       Impact factor: 2.089

View more
  15 in total

1.  Zoledronic acid in nine patients with transient osteoporosis of the hip.

Authors:  Gerasimos Evangelatos; George E Fragoulis; Alexios Iliopoulos
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

Review 2.  Transient osteoporosis of the hip: review of the literature.

Authors:  K Asadipooya; L Graves; L W Greene
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

3.  Transient Osteoporosis of the Hip on FDG PET/CT.

Authors:  Gary A Ulaner; Peter Sawan
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

4.  Transient regional osteoporosis of the ankle with shifting bone marrow edema pattern within the joint.

Authors:  Yasser Ragab; Yasser Emad; Sara Hassanein; Johannes J Rasker
Journal:  Radiol Case Rep       Date:  2022-06-17

5.  Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip.

Authors:  Cristina d'Agostino; Pietro Romeo; Vito Lavanga; Salvatore Pisani; Valerio Sansone
Journal:  Rheumatol Int       Date:  2014-11       Impact factor: 2.631

Review 6.  Treatment of bone marrow lesions (bone marrow edema).

Authors:  Erik F Eriksen
Journal:  Bonekey Rep       Date:  2015-11-25

7.  A case of regional migratory osteoporosis.

Authors:  J Spierings; S Bours; H R M Peeters
Journal:  Osteoporos Int       Date:  2017-10-24       Impact factor: 4.507

Review 8.  Evaluation of transient osteoporosis of the hip in magnetic resonance imaging.

Authors:  Dawid Szwedowski; Zaneta Nitek; Jerzy Walecki
Journal:  Pol J Radiol       Date:  2014-02-21

9.  Subchondral Insufficiency Fracture of the Femoral Head Caused by Excessive Lateralization of the Acetabular Rim.

Authors:  Tetsuya Kimura; Tomohiro Goto; Daisuke Hamada; Takahiko Tsutsui; Keizo Wada; Shoji Fukuta; Akihiro Nagamachi; Koichi Sairyo
Journal:  Case Rep Orthop       Date:  2016-05-11

10.  Transient Osteoporosis of the Hip: A Case Report.

Authors:  K Pande; T T Aung; J F Leong; I Bickle
Journal:  Malays Orthop J       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.